Short acting GLP-1 receptor agonist (injectable)
Lixisenatide 10 µg injection once daily
LIXI_SC_10UG_QD
Related
- All doses pooled: Lixisenatide injection
- Lixisenatide 20 ug subcutaneous once daily
- Lixisenatide 5 µg injection once daily
- Lixisenatide 30 µg injection once daily
- Lixisenatide 5 µg injection twice daily
- Lixisenatide 10 µg injection twice daily
- Lixisenatide 20 µg injection twice daily
- Lixisenatide 30 µg injection twice daily
- Lixisenatide 10 µg injection
- Lixisenatide 2.5 µg injection
- Lixisenatide 5 µg injection
- Lixisenatide 20 µg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.81 (0.01 to 64.25) | 0.41 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.87 (0.37 to 15.26) | 0.31 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.73 (0.06 to 4.23) | 0.58 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.80 (0.63 to 4.47) | 0.63 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.34 (0.69 to 12.73) | 0.44 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.86 (0.25 to 2.40) | 0.73 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.93 (0.06 to 15.29) | 0.45 |